Thermo Fisher Scientific Inc (NYSE:TMO) CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the transaction, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Thermo Fisher Scientific Inc (NYSE TMO) traded down $0.44 during trading on Friday, hitting $190.17. 1,151,902 shares of the stock traded hands, compared to its average volume of 1,545,246. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc has a 1 year low of $139.07 and a 1 year high of $201.20. The company has a market capitalization of $76,030.00, a P/E ratio of 20.78, a PEG ratio of 1.73 and a beta of 1.08.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. During the same quarter in the previous year, the firm posted $2.03 earnings per share. The company’s revenue was up 13.9% on a year-over-year basis. research analysts expect that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.19%.
TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) CEO Sells $9,419,500.00 in Stock” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.truebluetribune.com/2017/11/17/thermo-fisher-scientific-inc-tmo-ceo-sells-9419500-00-in-stock.html.
Several institutional investors have recently bought and sold shares of the company. Covington Capital Management raised its stake in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock valued at $374,000 after acquiring an additional 20 shares in the last quarter. Investment Centers of America Inc. raised its stake in Thermo Fisher Scientific by 1.6% in the second quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock worth $230,000 after buying an additional 21 shares in the last quarter. Fort Washington Investment Advisors Inc. OH raised its stake in Thermo Fisher Scientific by 0.4% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock worth $1,090,000 after buying an additional 23 shares in the last quarter. Azimuth Capital Management LLC raised its stake in Thermo Fisher Scientific by 0.8% in the first quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock worth $493,000 after buying an additional 25 shares in the last quarter. Finally, Bienville Capital Management LLC raised its stake in Thermo Fisher Scientific by 1.6% in the second quarter. Bienville Capital Management LLC now owns 1,687 shares of the medical research company’s stock worth $295,000 after buying an additional 27 shares in the last quarter. 83.78% of the stock is owned by hedge funds and other institutional investors.
Several research firms recently commented on TMO. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Bank of America Corporation reissued a “buy” rating and issued a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Barclays PLC reissued an “overweight” rating and issued a $215.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $205.71.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.